Publications - IR Sant Pau

Search

01/09/2024 Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics

Carri n-Barber , I, Monte, TCS, Triginer, L, Garc a-Villanueva, M, Corral, SG, Frutos, AR, Font, J, Galindo-Izquierdo, M, Polo, CDF, Gil, JJF, Moriano, C, Alvarez, ED, Bernab u, P, Vela-Casasempere, P, Cortes-Hern ndez, J, Moreno, SS, Narvaez-Garc a, J, Hern ndez-Mart n, A, Magallares, BP, Garc a, MP, Marras, C, Ramos, C, Gomez-Puerta, JA, Frade-Sosa, B, Fern ndez-Ortiz, A, Garcia-Aparicio, A, Altab s-Gonz lez, I, Hern ndez-Baldiz n, S, Ros-Vilamajo, I, Cirera, SG, Bufort, MG, Sala, L, Mart nez-Barrio, J, de Salazar, JRG, Heredia, S, Torrente-Segarra, V, Brandy-Garcia, AM, Del Amo, NDV, Fito-Manteca, C, Calvo-Alen, J, Pego-Reigosa, JM, R a-Figueroa, I. Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry

Narvaez-Garc a, J, Dominguez-Alvaro, M, Gal ndez-Agirregoikoa, E, Mendizabal, J, Alcazar, IA, Loricera, J, Garrido-Pu al, N, Casta eda, S, Moya, P, Larena, C, Estrada-Alarc n, P, Galisteo, C, Frutos, AR, Sanjuan, FO, Monte, TCS, Rocha, MV, Ubiaga, CLI, Garcia-Gonzalez, M, Blanco-Alonso, R. Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry

Fern ndez-Lozano, D, Dom nguez-Alvaro, M, Narvaez-Garc a, J, Garrido-Pu al, N, De Miguel, E, Estrada-Alarc n, P, Hern ndez-Rodr guez, I, Silva-Diaz, M, Belzunegui, JM, Moriano, C, S nchez-Mart n, J, Calvo, I, Aldasoro, V, Alcazar, LA, Loricera, J, Moya, P, Garc a-Villanueva, M, S nchez-Alonso, F, Casta eda, S, Hern ndez, JL, Blanco-Alonso, R. Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment

G mez, MLI, Escudero, PG, L pez, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, R a-Figueroa, I, Su rez, DVF, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Aragu s, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, G mez, IV, Vela-Casasempere, P, Merino, C, Mart nez, MI, Beriain, JAH, Roman, AMR, Calvo-Al n, J. Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study

Mysler, E, Ignatenko, S, Gordienko, A, Cort s-Hern ndez, J, Agmon-Levin, N, Narongroeknawin, P, Romanowska-Prochnicka, K, Shen, N, Cifersk , H, Kodera, M, Wei, JCC, Leszczynski, P, Lan, JL, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Dai, L, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, Magallares, BP, Sengupta, T, Sips, C, Lau, C, Avrameas, A, Oliver, SJ. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease

Zhang, YL, Tedeschi, S, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, J, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, D az, C, McCarthy, G, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Tarancon, LC, Stamp, L, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, FitzGerald, J, Dalbeth, N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Effectiveness of Rituximab in IgG4 Related Disease

Lopez-Gutierrez, F, Loricera, J, Hormigos, C, Nu ez, DF, Rodriguez-Laguna, M, Albarado, PM, G mez, MLI, Corominas, H, Silva-D az, M, Arribas, GG, Garcia-Aparicio, A, Urgelles, JF, Casafont-Sole, I, Calabuig, PM, Castaneda, E, Merino, C, Zas, R, Molina-Collada, J, Melero-Gonzalez, RB, Galindez-Agirregoikoa, E, Hern ndez-Mart n, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, V zquez, NM, Gallego-Flores, A, Ra a, NC, Veroz, R, Andres, M, Casta eda, S, Blanco-Alonso, R. Effectiveness of Rituximab in IgG4 Related Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis

Guerrero, MR, Moriano, C, Santos, CS, Herranz, LS, Garcia, JJ, Barranco, IC, Alvarez, ED. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study

De Silva, C, D az, C, Gamble, G, Horne, A, Doyle, A, Stamp, L, Dalbeth, N. Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

Quevedo-Rodr guez, A, Otero-Varela, L, S nchez-Alonso, F, P rez-Vera, Y, Manero-Ruiz, J, Campos-Fern ndez, C, Manrique-Arija, S, Vela-Casasempere, P, Mera-Varela, A, D az, C, Movasat, A, Garcia-Magallon, B, Ros-Vilamaj , I, Perez-Garcia, C, Castrejon, I. Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort

D'Alessandro, R, Rodolfi, S, Calot, A, Bebear, L, Campochiaro, C, Codullo, V, Del Galdo, F, Barranco, IC, Zanatta, E, Randone, SB, Boleto, G, Raffray, L, Chatelus, E, Cacoub, P, Le Joncour, A, Airo, P, Santos, CS, Lescoat, A, Avouac, J, Denton, C, Allanore, Y. Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study

Avil s, A, Plaza, Z, S nchez-Alonso, F, Casta eda, S, Fernandez-Gutierrez, B, D az, C, Font, P, Martinez, O, Giner, E, Senabre, JM, Rueda, A, Perez, A, Sanchez, G, Gonzalez, C, Garc a, J, Llorca, J, Gonzalez-Gay, MA, Andres, M. Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients

Escudero, PG, G mez, MLI, L pez, BM, Santos, DD, de Miera, FJTS, Dorta, AG, Beriain, JAH, R a-Figueroa, I, Santos, CS, Alvarez, ED, Mart nez, MI, Frade-Sosa, B, Urgelles, JF, Lizarzaburu, MS, Alonso, ER, Aragu s, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, Merino, C, Vela-Casasempere, P, G mez, IV, Filloy, JAM, Melero-Gonzalez, RB, Belando, CG, Boselli, G, Boteanu, AL, Su rez, DVF, Selaya, CC, Roman, AMR, Calvo-Al n, J. Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 The Gut-Airways Microbiome axis in COPD

Viglino, J, Perea, L, Garcia-Nuñez, M, Rodrigo-Troyano, A, Torrego, A, Domínguez, M, Miratlles, L, Quero, S, Willis, J, Saus, E, Gabaldón, T, Gea, J, Santos, MS, Agusti, A, Monsó, E, Sibila, O, Faner, R. The Gut-Airways Microbiome axis in COPD. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA3032. PMID:. IF:21.000(Q1/1D).

01/09/2024 Heterogeneity of comorbidities captured by European national severe asthma registries in SHARP CRC

Rink, S, Freeman, A, Bansal, AT, Bossios, A, Frankemoelle, B, Schleich, F, Sont, JK, Singh, M, Bieksiene, K, Bourdin, A, Canonica, GW, Csoma, Z, Gemicioglu, B, Grisle, I, Popovic, SG, Hromis, S, Korn, S, Kuna, P, Loureiro, C, Mihaltan, F, Porsbjerg, C, Ramos-Barbon, D, Renaud, L, Sergejeva, S, Ten Brinke, A, Yasinska, V, Zervas, E, Skrgat, S, Kurukulaaratchy, R. Heterogeneity of comorbidities captured by European national severe asthma registries in SHARP CRC. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA1763. PMID:. IF:21.000(Q1/1D).

01/09/2024 Initial data analysis of the SHARP CRC patient population reveals a large heterogeneity among European patients with severe asthma

Fouka, E, Bansal, AT, Jaun, F, Håkansson, KEJ, Bieksiene, K, Bourdin, A, Butler, M, Canonica, GW, Csoma, Z, Dahlén, B, Gemicioglu, B, Grisle, I, Heaney, L, Heffler, E, Hromis, S, Kuna, P, Leuppi, J, Louis, R, Oureiro, C, Lúoviksdóttir, D, Mihaltan, F, Popovic, SG, Ramos-Barbon, D, Sedlak, V, Sergejeva, S, Skrgat, S, Ten Brinke, A, Yasinska, V, Zervas, E, Schleich, F, Porsbjerg, C, Bossios, A. Initial data analysis of the SHARP CRC patient population reveals a large heterogeneity among European patients with severe asthma. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA4008. PMID:. IF:21.000(Q1/1D).

01/09/2024 European physician perspectives on multimorbidity in severe asthma: findings from SHARP CRC

Rink, S, Freeman, A, Bansal, AT, Bossios, A, Frankemölle, B, Schleich, F, Sont, JK, Singh, M, Bieksiene, K, Bourdin, A, Canonica, GW, Csoma, Z, Gemicioglu, B, Grisle, I, Popovic, SG, Hromis, S, Korn, S, Kuna, P, Loureiro, C, Mihaltan, F, Porsbjerg, C, Ramos-Barbon, D, Renaud, L, Sergejeva, S, Ten Brinke, A, Yasinska, V, Zervas, E, Skrgat, S, Kurukulaaratchy, R. European physician perspectives on multimorbidity in severe asthma: findings from SHARP CRC. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2149. PMID:. IF:21.000(Q1/1D).

01/09/2024 Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study

Jaun, F, Bánsal, AT, Fouka, E, Hakansson, KEJ, Bieksiene, K, Bourdin, A, Butler, M, Canonica, GW, Csoma, Z, Dahlén, B, Gemicioglu, B, Grisle, I, Heaney, L, Heffler, E, Hromis, S, Kuna, P, Mihaltan, F, Leuppi, JD, Loureiro, C, Louis, R, Luoviksdóttir, D, Ramos-Barbon, D, Popovic, SG, Samitas, K, Sedlak, V, Sergejeva, S, Skrat, S, Ten Brinke, A, Yasinska, V, Zervas, E, Schleich, F, Porsbjerg, C, Bossios, A. Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA1248. PMID:. IF:21.000(Q1/1D).

01/09/2024 The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries

Bourdin, A, Bansal, AT, Di Matteo, S, Giacomo, CM, Heaney, B, Ten Brinke, A, Csoma, Z, Dahlen, B, Djukanovic, R, Heaney, L, Kuna, P, Heffler, E, Louis, R, Porsbjerg, C, Ramos-Barbon, D, Skrgat, S, Paulsson, T, Mascialino, B. The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA1176. PMID:. IF:21.000(Q1/1D).

01/09/2024 Stoma Stent in a traqueotomy decanulation process. Experience in a cohort of patients with prolongued mechanical ventilation

Otero, ARP, Pujal, P, Rafecas, A, Panadero, C, Penacoba, P, Puy, C, Segura, M, Anton, PA. Stoma Stent in a traqueotomy decanulation process. Experience in a cohort of patients with prolongued mechanical ventilation. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2615. PMID:. IF:21.000(Q1/1D).

01/09/2024 Real-world effectiveness of switching to Benralizumab in patients with severe asthma in the Catalan population. Catalan Society of Pulmonology (SOCAP) Registry

Arismendi, E, Muñoz, M, Crespo, A, Ausin, P, Castillo, JA, Curto, E, Lapuente, A, Arguedas, AM, Martínez-Rivera, C, Monserrate, D, Muñoz, X, Ojanguren, I, Palones, E, Paredes, M, Pilia, F, Picado, C, Sabater, G, Sabadell, C, Sogo, A, Cañete, C. Real-world effectiveness of switching to Benralizumab in patients with severe asthma in the Catalan population. Catalan Society of Pulmonology (SOCAP) Registry. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA3926. PMID:. IF:21.000(Q1/1D).

01/09/2024 Molecular insights into hypoxic burden physiopathology in OSA: a proteomic perspective

Pinilla, L, Dodani, K, Benitez, I, Esmaeli, N, Gracia-Lavedán, E, Torres, G, Minguez, O, Martinez, D, Martínez-García, MA, Abad, J, Masdeu, MJ, Mediano, O, Muñoz, C, Cabriada, V, Duran-Cantolla, J, Mayos, M, Coloma, R, Montserrat, JM, De la Peña, M, Cano-Pumarega, I, Barbé, F, Azarbarzin, A, Sanchez-De-la-Torre, M. Molecular insights into hypoxic burden physiopathology in OSA: a proteomic perspective. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2693. PMID:. IF:21.000(Q1/1D).

01/09/2024 Improvement in lung function after six months of treatment with extrafine formulation single-inhaler triple therapy (efSITT) in patients with asthma-TriMaximize Study

Gessner, C, Bogoevska, V, Nachtigall, D, Russell, R, Ulrik, CS, Pohl, W, Plaza, V, Bourdin, A, Criée, CP, Trinkmann, F. Improvement in lung function after six months of treatment with extrafine formulation single-inhaler triple therapy (efSITT) in patients with asthma-TriMaximize Study. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2121. PMID:. IF:21.000(Q1/1D).

01/09/2024 Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study

Greulich, T, Bogoevska, V, Nachtigall, D, Russell, R, Suppli, C, Wolfgang, U, Pohl, W, Plaza, V, Bourdin, A, Baumeister, S, Gessner, C. Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA3907. PMID:. IF:21.000(Q1/1D).

01/09/2024 Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).

01/09/2024 ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

Barba, A, López-Vilaró, L, Ferre, M, Majem, M, Martinez-Recio, S, Bell, O, Arranz, MJ, Salazar, J, Sullivan, I. ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics. 2024; 16(9)DOI:10.3390/pharmaceutics16091121. PMID:39339159. IF:5.500(Q1/1D).

01/09/2024 Pancreatic adenocarcinoma associated with intraductal papillary mucinous neoplasm: a case series

Prat, A, Piñol, D, Espadaler, I, Campazas, I, Espinosa, I, Fusté, V, Szafranska, J, Fumagalli, C. Pancreatic adenocarcinoma associated with intraductal papillary mucinous neoplasm: a case series. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/09/2024 NKX2.2 expression in Ewing sarcoma: differences in sensitivity between pre-treatment biopsy and surgical specimen - a case series

Prat, A, Di Muro, MA, Acosta, SF, Vazquez, T, Rosell, SB, Orellana, R, Fumagalli, C. NKX2.2 expression in Ewing sarcoma: differences in sensitivity between pre-treatment biopsy and surgical specimen - a case series. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/09/2024 Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor

Carrillo-García, J, Hindi, N, Conceicao, M, Sala, MA, Ugalde, A, López-Pousa, A, Bagué, S, Sevilla, I, Vicioso, L, Ramos, R, Martínez-Trufero, J, Mateo, MCG, Cruz, J, Hernández-León, CN, Redondo, A, Mendiola, M, García, JM, Hernández, JE, Alvarez, R, Agra, C, de Juan-Ferré, A, Valverde, C, Cano, JM, de Sande, LM, Pérez-Fidalgo, JA, Lavernia, J, Marcilla, D, Gutiérrez, A, Moura, DS, Martín-Broto, J. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. EUROPEAN JOURNAL OF CANCER. 2024; 209DOI:10.1016/j.ejca.2024.114270. PMID:39142211. IF:7.100(Q1/2D).

01/09/2024 Voice Outcome After Carbon Dioxide Transoral Laser Microsurgery for Glottic Cancer According to the European Laryngological Society Classification of Cordectomy Types – A Systematic Review

Sjogren E., Hendriksma M., Piazza C., Hartl D.M., Suarez C., Cohen O., de Bree R., Quer M., Poorten V.V., Rodrigo J.P., Civantos F., Genden E., Kowalski L.P., Makitie A., Shaha A., Takes R.P., Sanabria A., Guntinas-Lichius O., Rinaldo A., Ferlito A.. Voice Outcome After Carbon Dioxide Transoral Laser Microsurgery for Glottic Cancer According to the European Laryngological Society Classification of Cordectomy Types – A Systematic Review. JOURNAL OF VOICE. 2024; 38(5)DOI:10.1016/j.jvoice.2022.03.003. PMID:35422356. IF:2.400(Q1/1D).

01/09/2024 HPV-associated multiphenotypic sinonasal carcinoma. Tumour with indolent behaviour? A case-control study

Ballús, DP, López, L, Bagué, S, Gonzalez, A, Holgado, A, Gras, JR, Szafranska, J. HPV-associated multiphenotypic sinonasal carcinoma. Tumour with indolent behaviour? A case-control study. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/09/2024 Sinonasal hamarthomas: a rare entity with a challenging diagnosis - how an accurate diagnosis impacts clinical and therapeutic management

Vilaró, LL, Prat, A, Piñol, D, Catasús, L, Rosell, SB, Casasayas, M, Cabrerizo, JRG, Szafranska, J. Sinonasal hamarthomas: a rare entity with a challenging diagnosis - how an accurate diagnosis impacts clinical and therapeutic management. VIRCHOWS ARCHIV. 2024; 485DOI:. PMID:. IF:3.100(Q2/3D).

01/09/2024 Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study

Bobes, A, Tormo, M, Diaz-Beya, M, Beneit, P, Botella, C, Moreno, AF, Mayol, AS, Sangerman, MA, Bermejo, AY, Amigo, MD, Labrador, J, Guinon, AG, Garrido, A, Serrano, J, Polo, SV, Fortes, MG, Sayas, MJ, Bergua, JM, Olave, MT, Vall-Llovera, F, Bargay, J, Sanchez, MP, Boyero, RG, Diaz-Lopez, A, de la Fuente, A. Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study. Clinical Lymphoma Myeloma & Leukemia. 2024; 24DOI:. PMID:. IF:2.700(Q2/4D).

01/09/2024 Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria

Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(9)DOI:10.3390/antibiotics13090874. PMID:39335047. IF:4.600(Q1/2D).

01/09/2024 Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles

Parladé, E, García-Leon, A, Voltà-Durán, E, Unzueta, U, Mangues, R, Casanova, I, Villaverde, A, Váquez, E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2024; 202DOI:10.1016/j.ejpb.2024.114410. PMID:39004320. IF:4.300(Q1/2D).

01/09/2024 Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients

Balius, R, Pedret, C, Estrada-Alarcón, P, Corominas, H. Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients. European Journal Of Rheumatology. 2024; 11DOI:10.5152/eurjrheum.2022.21131. PMID:36052637. IF:(Q/D).

01/09/2024 A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight

Mercader-García, P, Silvestre, JF, Navarro-Triviño, FJ, Giménez-Arnau, AM, Pastor-Nieto, MA, Cordoba-Guijarro, S, Melé-Ninot, G, Tous-Romero, F, González-Pérez, R, Ruiz-González, I, Sánchez-Pérez, J, Gática-Ortega, ME, Sánchez-Pedreño, P, Miquel-Miquel, J, Ortiz-Frutos, J, Carrascosa, JM, Serra-Baldrich, E, Sanz-Sanchez, T, Soria-Aledo, V, Carrillo, A, Borrego, L. A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight. CONTACT DERMATITIS. 2024; 91(3)DOI:10.1111/cod.14639. PMID:38965446. IF:4.600(Q1/1D).

01/09/2024 [Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.

Rivera-Díaz R, Carrascosa Carrillo JM, Alfonso Zamora S, Navarro Valdivieso JP, Muñoz Cabello B, Ros Abarca S, Soria de Francisco JM, Daudén Tello E. [Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.. Actas Dermo-Sifiliograficas. 2024; 115(8)DOI:10.1016/j.ad.2024.07.012. PMID:38972580. IF:(Q/D).

01/09/2024 Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial

Puig, L, Costanzo, A, de Jong, EMGJ, Torres, T, Warren, RB, Wapenaar, R, Wegner, S, Gorecki, P, Gramiccia, T, Jazra, M, Buyze, J, Conrad, C. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01245-6. PMID:39153060. IF:4.200(Q1/1D).

31/08/2024 Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Piñana, JL, Giménez, E, Vázquez, L, Marcos, MA, Guerreiro, M, Duarte, R, Pérez, A, de Miguel, C, Espigado, I, González-Vicent, M, Suarez-Lledó, M, García-Cadenas, I, Martino, R, Cedillo, A, Rovira, M, de la Cámara, R, Navarro, D, Solano, C. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterranean Journal of Hematology and Infectious Diseases. 2024; 16(1)DOI:10.4084/MJHID.2024.065. PMID:39258183. IF:1.500(Q3/8D).